Phase 1 · Chicago area, IL
Phase 1 clinical trials in Chicago area, IL
53 recruiting studies have a site in the Chicago area. This page includes nearby cities such as Evanston, Oak Brook, Oak Lawn, Park Ridge.
53 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
EpiDestiny, Inc.
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Janssen Research & Development, LLC
- Location
- Chicago, IL + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1/Phase 2
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
UniQure Biopharma B.V.
- Location
- Chicago, IL + 9 other US sites
- Eligibility basics
- Ages 18–65 · Men only
- RecruitingPhase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Sarepta Therapeutics, Inc.
- Location
- Chicago, IL + 10 other US sites
- Eligibility basics
- Ages 2+ · Men only
- RecruitingPhase 1/Phase 2
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
COUR Pharmaceutical Development Company, Inc.
- Location
- Chicago, IL + 44 other US sites
- Eligibility basics
- Ages 12–35
- RecruitingPhase 1
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Allogene Therapeutics
- Location
- Chicago, IL + 15 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 1
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Biogen
- Location
- Chicago, IL + 11 other US sites
- Eligibility basics
- Ages 3+
- RecruitingPhase 1/Phase 2
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
Jaguar Gene Therapy, LLC
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 2–9
- RecruitingPhase 1/Phase 2
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
Astellas Gene Therapies
- Location
- Chicago, IL + 3 other US sites
- Eligibility basics
- Up to age 3 · Men only
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Bristol-Myers Squibb
- Location
- Chicago, IL + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1/Phase 2
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur, a Sanofi Company
- Location
- Chicago, IL + 78 other US sites
- Eligibility basics
- Ages 18–45
- RecruitingPhase 1/Phase 2
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
Otsuka Pharmaceutical Factory, Inc.
- Location
- Chicago, IL
- Eligibility basics
- Ages 35–70
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Nkarta, Inc.
- Location
- Chicago, IL + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc.
- Location
- Chicago, IL + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 1/Phase 2
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Mahzi Therapeutics
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 2–25
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
MavriX Bio, LLC
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 4–50
- RecruitingPhase 1/Phase 2
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Solid Biosciences Inc.
- Location
- Chicago, IL + 11 other US sites
- Eligibility basics
- Ages 0 mo–17 · Men only
- RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB Biopharma SRL
- Location
- Chicago, IL + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Sonoma Biotherapeutics, Inc.
- Location
- Chicago, IL + 8 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1
Study of BHV-1400 in IgA Nephropathy
Biohaven Therapeutics Ltd.
- Location
- Hinsdale, IL + 13 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Nkarta, Inc.
- Location
- Chicago, IL + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
Achilles Tendinopathy Embolization
Joint & Vascular Institute
- Location
- Libertyville, IL
- Eligibility basics
- Ages 25–80
- RecruitingPhase 1/Phase 2
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
Aspa Therapeutics
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Up to age 2
- RecruitingPhase 1/Phase 2
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Noveome Biotherapeutics, formerly Stemnion
- Location
- Evanston, IL + 7 other US sites
- Eligibility basics
- Ages 0 mo–2 mo
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.